20 results about "Pemphigus" patented technology

The present invention relates to antibodies that bind to IgE and their use in the treatment of autoimmune diseases, particularly Bullous Pemphigoid (BP) and Chronic Spontaneous Urticaria (CSU). The anti-IgE antibodies comprise a variant Fc domain that binds to the Fc receptor FcRn with increased affinity relative to a wild-type Fc domain. The anti-IgE antibodies may comprise a variant Fc domain comprising the amino acids Y, T, E, K, F and Y at EU positions 252, 254, 256, 433, 434 and 436, respectively, wherein the variant Fc domain binds to human FcRn with increased affinity relative to a wild-type human IgG Fc domain.

A platform for therapy provides a multi-target therapeutic molecule comprising an anti-CD3 antigen binding fragment of an anti-CD3 antibody linked with a linker to two or more auto-antigen(s). The auto-antigens include Dsg1, Dsg3, bullous pemphigoid antigen 180, bullous pemphigoid antigen 230, MuSK, anti-phospholipase A2 Receptor. A pharmaceutical composition comprises a disclosed multi-target therapeutic molecule is disclosed. Methods of treating diseases using the disclosed molecules are disclosed

Methods for treating bullous pemphigoid in a subject are provided. In one aspect, the methods comprise administering to a subject having bullous pemphigoid one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

The present invention relates to antibodies that bind to IgE and their use in the treatment of autoimmune diseases, particularly Bullous Pemphigoid (BP) and Chronic Spontaneous Urticaria (CSU). The anti-IgE antibodies comprise a variant Fc domain that binds to the Fc receptor FcRn with increased affinity relative to a wild-type Fc domain. The anti-IgE antibodies may comprise a variant Fc domain comprising the amino acids Y, T, E, K, F and Y at EU positions 252, 254, 256, 433, 434 and 436, respectively, wherein the variant Fc domain binds to human FcRn with increased affinity relative to a wild-type human IgG Fc domain.

The invention belongs to the field of biological medicine, and provides an antibody combined with pemphigus vulgaris specific antigen peptide and application of the antibody. According to the principle of a phage display technology, a constructed library is subjected to in-vitro affinity screening, phages are combined with a target antigen Dsg3, non-specific binders are eluted, the phages tightly combined with the antigen are reserved, and the pemphigus vulgaris specific antigen peptide is obtained. Then, amplifying and carrying out affinity enrichment for multiple rounds; and carrying out multiple rounds of panning, and after 3-5 rounds of screening, obtaining phage clones with strong binding capacity with Dsg3 and high specificity.

The present invention relates to a CXCL8 inhibitor that is useful for the prevention and / or treatment of ocular mucous membrane pemphigoid and / or oral mucous membrane pemphigoid.

The present invention relates to a diagnostic composition comprising at least one peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (VDELERIRRSILPYGDSMDRIEKDR), SEQ ID NO: 2 (GGAGSLGAGGAFGEA), SEQ ID NO: 35 (GPAGPPGHPGPPGPR), SEQ ID NO: 4 (EGLITLTELADSLLS), SEQ ID NO: 5 (EFQYLTGGLIEPQVH), SEQ ID NO: 6 (SSHMLTDTKTGLHFN), SEQ ID NO: 7 (FIPGPPGPPGPPGPR), SEQ ID NO: 8 (INEAIEQGTIDKALV), SEQ ID NO: 9 (AFGEAAGDRGPYGTDI) and SEQ ID NO: 10 (LITLTELADSLLSRL). Furthermore, the present invention relates to an in vitro method for detecting the presence or absence of a disease selected from the group of bullous pemphigoid, Parkinson's disease, and a neurological disorder comprising testing the binding of at least one peptide as identified in any of the preceding claims for binding to autoantibodies obtained from a subject suspected of suffering from one of said diseases.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation in the skin, e.g., atopic dermatitis, eczema other than atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, scleroderma (including systemic sclerosis), dermatomyositis, epidermolysis bullosa, mastocytosis, keloids, acne, rosacea, or bullous pemphigoid, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody (Afimkibart).

A method of treating a subject suffering from an immune-mediated disease (e.g., IgA nephropathy, primary membranous nephropathy, an antibody-mediated rejection, lupus nephritis, systemic lupus erythematosus (SLE), Graves' Disease, Myasthenia Gravis, Anti-PLA2R positive Membranous Glomerulonephritis (aMN), Pemphigus, Sjögren's syndrome, and / or Anti-NMDA encephalitis) by administering to the subject a regimen of at least five doses of felzartamab and measuring a level of CD19+CD27hiCD38hi plasmablasts, a level of CD19+ B lymphocytes, or levels of CD19+CD27hiCD38hi plasmablasts and CD19+ B lymphocytes in a blood sample taken from the subject.

Disclosed herein are methods for treating pemphigus in a human patient in need thereof comprising administering to the human patient a dose of at least 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) once a day (QD) or twice a day (BID).

The present invention relates to a composition containing an Eclipta prostrata extract-derived compound as an active component for preventing, alleviating or treating pemphigus. The compound of Chemical Formula 1, which is the compound derived from an Eclipta prostrata extract of the present invention, has almost no cytotoxicity and exhibits antioxidant activity (reduction of reactive oxygen species (ROS) generation), and an excellent inhibitory effect on keratinocyte dissociation induced by AK23 (Anti-Desmoglein 3), thereby being able to be usefully used for preventing, alleviating or treating pemphigus.

The present invention provides a composition comprising a first polypeptide comprising a dimerization domain and a first fragment of an extracellular domain of DSG1 or DSG3 or an analog or derivative thereof, and a second polypeptide comprising a dimerization domain and a second fragment of an extracellular domain of DSG1 or DSG3 or an analog or derivative thereof. Also provided are polypeptides comprising a fragment of the extracellular domain of DSG1 or DSG3 comprising at least one mutation that increases solubility, reduces aggregation, or both, or is free of extracellular domains 3 and 4. Also provided are pharmaceutical compositions comprising the compositions, polypeptides, nucleic acid systems and nucleic acid molecules encoding the polypeptides of the compositions of the invention, and methods of using the compositions or polypeptides for treatment and for determining the suitability of treatment; and methods of making the compositions or proteins.

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

The present invention relates to C5aR1 inhibitors for use in the prevention and / or treatment of ocular mucous membrane pemphigoid and / or oral mucous membrane pemphigoid.

The invention belongs to the field of biological medicine, and provides an antibody combined with pemphigus vulgaris specific antigen peptide and application of the antibody. According to the principle of a phage display technology, a constructed library is subjected to in-vitro affinity screening, phages are combined with a target antigen Dsg3, non-specific binders are eluted, the phages tightly combined with the antigen are reserved, and the pemphigus vulgaris specific antigen peptide is obtained. Then, amplifying and carrying out affinity enrichment for multiple rounds; and carrying out multiple rounds of panning, and after 3-5 rounds of screening, obtaining phage clones with strong binding capacity with Dsg3 and high specificity.

The present invention provides, inter alia, methods of treating a pruritic or inflammatory skin disease or disorder, or pruritus associated with a certain disease or disorder, using anti-OSMR [beta] antibodies, comprising methods of treating pruritus associated with atopic dermatitis, chronic kidney disease-associated pruritus, uremic pruritus or prurigo nodularis, chronic idiopathic pruritus, chronic idiopathic urticaria, chronic spontaneous urticaria, skin amyloidosis, chronic simple moss, psoriasis plaque, moss planus, inflammatory lepidosis, and the like. The present invention relates to methods for treating mastocytoplasia and bullous pemphigus, comprising the step of administering an anti-OSMR [beta] antibody to a subject in need of treatment at a therapeutically effective dose and administration interval relative to a control for a treatment cycle sufficient to ameliorate, stabilize, or alleviate one or more symptoms of the disease or condition.

A composition is provided comprising a first polypeptide comprising a first fragment or analog or derivative of the extracellular domain of DSG1 or DSG3 and a dimerizing domain, and a second polypeptide comprising a second fragment or analog or derivative of the extracellular domain of DSG1 or DSG3 and a dimerizing domain. Polypeptides comprising fragments of the extracellular domain of DSG1 or DSG3 that include at least one mutation that increases solubility, decreases aggregation, or both, or that lack extracellular domains 3 and 4. Also provided are the compositions of the present invention, polypeptides, nucleotide systems and molecules encoding the polypeptides of the present invention, pharmaceutical compositions, methods for therapeutic use of the compositions or polypeptides and methods for determining suitability for therapeutic use, and methods for producing the compositions or proteins.

The invention discloses application of D74 as a biomarker in preparation of a kit for evaluating or diagnosing bullous pemphigus. The CD74 expression of the skin lesion part of a to-be-detected subject and the CD74 expression of the corresponding position of the normal skin are compared, bullous pemphigus is positive if the CD74 at the skin lesion part is linearly deposited along the true epidermis junction, and the normal tissue is not positively stained. A BP characteristic gene module is identified by adopting a multi-omics integration analysis strategy, and it is found that the CD74 expression level is remarkably related to the eosinophilic granulocyte infiltration degree; the potential of the aptamer as a diagnostic biomarker is verified in patient tissues through immunohistochemistry, the detection sensitivity is 100%, the specificity is 83.3%, the positive predictive value is 78.9%, and the accuracy is 89.7%.

The present invention relates to the field of biomedical materials, regenerative medicine and biotechnology, specifically to a method for producing a type I collagen solution from collagen-containing natural raw materials, and also to a method for producing a wound dressing based on type I collagen. The method for producing a type I collagen solution from collagen-containing natural raw materials does not require the use of complex equipment (in particular, centrifuges) and is therefore technologically simpler and requires less time and labor to produce type I collagen from collagen-containing natural raw materials. Moreover, said method is characterized by the short duration of the collagen extraction stage (with no need to perform a re-extraction step), as well as a high collagen yield. In addition, the type-I-collagen-based wound dressing produced using the method according to the invention is non-toxic and holds promise for the topical treatment of human skin defects, as well as for use in the case of second- and third-degree burns, and for the treatment of slow-healing shallow granulating wounds in the regeneration stage, post-traumatic wounds, trophic ulcers of any etiology or localization, bedsores, epidermolysis bullosa, and various types of pemphigus.